相关实验视频

Updated: Feb 4, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

炎症和癌症:分子机制和治疗点

Xiaodie Liu¹, Ziyuan Wang², Huirong Zhu¹

¹Department of Medical Oncology & Cancer Institute of Integrative Medicine Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai China.

|February 3, 2026

概括

炎症驱动瘤生长和对治疗的抵抗. 了解其复杂的分子相互作用是开发新的抗炎和抗瘤治疗的关键.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

炎症是癌症发病,进展和治疗耐药性的关键因素.
内部因素 (基因组不稳定,代谢变化) 和外部因素 (免疫功能障碍,微生物失衡) 驱动炎症诱导的致癌.
当前的癌症疗法可以矛盾地增加炎症,导致化学抵抗和复发.

研究的目的:

系统地审查炎症诱导瘤的调节网络.
总结关于炎症点和组合疗法的临床前数据.
为突出研究细胞特异性炎症信号传递对准确医学的需求.

主要方法:

系统的文献审查和综合现有关于炎症和瘤相互作用的研究.
对针对炎症途径有效性的临床前数据的分析.
识别细胞特异性炎症信号调节方面的知识差距.

主要成果:

阐明了炎症诱导瘤的"内部驱动力-外部吸引力"模型.
针对炎症调解剂和组合疗法的验证的临床前疗效.
确定了细胞特异性炎症信号传递的研究不足的区域,以及其与抗瘤作用的平衡.

结论:

对炎症和瘤交叉的全面理解对于有效的癌症治疗至关重要.
针对炎症通路,特别是以细胞特异的方式,对精确瘤学具有前景.
需要进一步的研究来将研究结果转化为抗炎抗瘤疗法的临床策略.

关键词:

药物耐药性耐药性药物耐药性这是一种炎症炎症炎症炎症.个性化治疗是个性化的治疗.治疗目标是治疗的目标.瘤是一个瘤.

更多相关视频

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

相关概念视频

Inflammation

Inflammation

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Reaction Mechanisms

Reaction Mechanisms

Chemical reactions often occur in a stepwise fashion, involving two or more distinct reactions taking place in a sequence. A balanced equation indicates the reacting species and the product species, but it reveals no details about how the reaction occurs at the molecular level. The reaction mechanism (or reaction path) provides details regarding the precise, step-by-step process by which a reaction occurs.
For instance, the decomposition of ozone appears to follow a mechanism with two steps:

Therapeutic Index

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...